New Risk • May 16
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended March 2025. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported March 2025 fiscal period end). Share price has been highly volatile over the past 3 months (22% average weekly change). Revenue is less than US$1m (₩279m revenue, or US$186k). 공시 • Feb 27
ViGenCell Inc., Annual General Meeting, Mar 26, 2026 ViGenCell Inc., Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 222, banpo-daero, seocho-gu, seoul South Korea New Risk • Feb 24
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩125.7b (US$87.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Revenue is less than US$1m (₩279m revenue, or US$193k). Minor Risks Latest financial reports are more than 6 months old (reported March 2025 fiscal period end). Market cap is less than US$100m (₩125.7b market cap, or US$87.1m). New Risk • Dec 01
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Revenue is less than US$1m (₩279m revenue, or US$190k). Minor Risks Latest financial reports are more than 6 months old (reported March 2025 fiscal period end). Market cap is less than US$100m (₩125.6b market cap, or US$85.5m). New Risk • Nov 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (₩279m revenue, or US$189k). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩93.1b market cap, or US$63.2m). New Risk • Oct 09
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Revenue is less than US$1m (₩279m revenue, or US$197k). Minor Risk Market cap is less than US$100m (₩73.0b market cap, or US$51.5m). New Risk • Jul 15
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (₩279m revenue, or US$203k). Minor Risks Share price has been volatile over the past 3 months (9.5% average weekly change). Market cap is less than US$100m (₩77.7b market cap, or US$56.4m). 공시 • Feb 27
ViGenCell Inc., Annual General Meeting, Mar 27, 2025 ViGenCell Inc., Annual General Meeting, Mar 27, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 222, banpo-daero, seocho-gu, seoul South Korea 공시 • Jan 25
Gaeun Global Co.,Ltd completed the acquisition of 11.36% stake in ViGenCell Inc. (KOSDAQ:A308080) from Boryung Corporation (KOSE:A003850). Gaeun Global Co.,Ltd agreed to acquire 11.36% stake in ViGenCell Inc. (KOSDAQ:A308080) from Boryung Corporation (KOSE:A003850) for KRW 7.9 billion on December 18, 2024.
Gaeun Global Co.,Ltd completed the acquisition of 11.36% stake in ViGenCell Inc. (KOSDAQ:A308080) from Boryung Corporation (KOSE:A003850) on January 23, 2025. New Risk • Dec 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (₩56m revenue, or US$39k). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩65.3b market cap, or US$46.0m).